Welcome to our dedicated page for Selectquote SEC filings (Ticker: SLQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SelectQuote, Inc. filings document formal disclosures for a public insurance distribution and healthcare services company. Recent Form 8-K reports furnish quarterly and annual operating results, investor presentation exhibits, and segment information for Senior, Healthcare Services, Life, and SelectRx-related activity.
The company’s regulatory filings also cover capital-structure matters, including a senior secured credit facility and revolving credit facility, as well as NYSE continued-listing compliance disclosures. Governance records include annual meeting voting results for director elections, auditor ratification, and advisory executive-compensation matters, while amended event reports document corrections to previously furnished earnings materials.
SelectQuote, Inc. director Denise L. Devine reported an open-market sale of 4,000 shares of common stock on May 19, 2026 at a weighted average price of $1.02 per share. After this transaction, she directly holds 367,214 shares of SelectQuote common stock.
SelectQuote, Inc. reported solid third‑quarter fiscal 2026 results, with consolidated revenue of $430.9 million and net income of $40.2 million, both up from the prior year period. Adjusted EBITDA rose to $44.6 million, reflecting stronger profitability.
The Senior segment generated revenue of $182.9 million and Adjusted EBITDA of $58.6 million, helped by 175,557 approved Medicare Advantage policies and a favorable $14 million change in estimate to commissions receivable. Healthcare Services produced revenue of $199.4 million, Adjusted EBITDA of $5.3 million, and served 116,616 SelectRx members.
Life segment revenue reached $47.9 million with Adjusted EBITDA of $6.1 million. On a rolling 12‑month basis, total revenue per Medicare Advantage/Medicare Supplement policy was $2,490 and the revenue‑to‑customer‑acquisition‑cost multiple improved to 6.7x. The company reaffirmed full‑year 2026 guidance, targeting revenue of $1.61–$1.71 billion and Adjusted EBITDA of $90–$100 million.
SelectQuote, Inc. reported that it received a notice from the New York Stock Exchange stating its common stock no longer meets the NYSE’s $1.00 minimum average closing price requirement over a consecutive 30 trading-day period. The company has six months from March 19, 2026 to regain compliance.
SelectQuote plans to notify the NYSE of its intent to cure the deficiency, monitor its share price and, if needed, pursue actions that may require stockholder approval, such as potential corporate actions affecting the share price. During the cure period, its shares remain listed on the NYSE, assuming compliance with all other listing standards.
In the accompanying press release, the company highlighted a new $415 million credit facility extending most debt maturities to 2031 and projected fiscal 2026 operating cash flow of $25 million to $35 million, which it believes supports liquidity while it works to maintain its NYSE listing.
SelectQuote, Inc. director Chris Wolfe reported acquiring shares through equity compensation. On February 28, 2026, he exercised or converted restricted stock units, acquiring 9,502 shares of common stock at a price of $0.00 per share.
The filing also shows 9,502 restricted stock units tied to this transaction, with 19,006 restricted stock units held after the transaction and 9,502 common shares held directly. These awards were granted under SelectQuote’s 2020 Omnibus Incentive Plan and vest in three annual installments, subject to continued Board service.
SelectQuote, Inc. Chief Financial Officer Clement Ryan Moore reported equity award activity involving restricted stock units and common shares. On February 28, 2026, restricted stock units covering 20,834 shares were converted into an equal number of common shares, and 7,219 common shares were surrendered at $0.86 per share to cover tax withholding obligations. On March 1, 2026, an additional 6,234 restricted stock units were converted into 6,234 common shares, with 2,161 common shares surrendered at $0.86 per share for taxes. After these transactions, Moore directly held 322,393 shares of SelectQuote common stock. The restricted stock units were granted under the company’s 2020 Omnibus Incentive Plan and each unit represents a contingent right to receive one common share, vesting in three- or four-year annual installments, subject to continued employment.
SelectQuote director Srdjan Vukovic reported equity awards and a conversion tied to board service. On November 11, 2025, he received a grant of 106,250 restricted stock units under SelectQuote’s 2020 Omnibus Incentive Plan. Each unit represents a contingent right to one share of common stock.
On February 28, 2026, 9,502 restricted stock units were converted into 9,502 shares of common stock at a price of $0.00 per share, leaving 19,006 restricted stock units and 9,502 common shares held directly after the transactions. One award vests in full on the date of SelectQuote’s 2026 Annual Meeting of Stockholders, while another vests in three equal annual installments, in each case conditioned on continued service on the Board of Directors.
SelectQuote, Inc. president Grant Robert Clay reported open-market purchases of company stock made through family trusts. On February 11, 2026, three irrevocable trusts for his minor children bought 39,366, 39,514, and 40,021 shares of SelectQuote common stock at weighted average prices of $0.889, $0.886, and $0.875 per share, respectively, for a total of 118,901 shares.
After these transactions, each child’s trust held a little over 100,000 shares. Clay also reports 2,891,334 shares held directly, 1,242,000 shares held indirectly as trustee of the Robert Clay Grant Irrevocable Trust, and 1,089,369 shares beneficially owned through Haakon Capital, LLC, where he has a one‑third ownership interest.
Morgan Stanley reported its beneficial ownership of SelectQuote, Inc. common stock at 4.99% of the class, representing 8,982,943 shares. These shares are held with shared voting power over 8,976,678 shares and shared dispositive power over 8,982,943 shares, with no sole voting or dispositive power.
The filing is an amendment that restates a prior ownership report because Morgan Stanley’s ability to exercise certain one-for-one convertible warrants is limited by a purchase agreement. Morgan Stanley certifies the position is held in the ordinary course of business and not for the purpose of influencing control of SelectQuote.